The FDA’s Office of Prescription Drug Promotion (OPDP) issued an Untitled Letter, backdated to September 23, to Tracey M. Henderson, MS, MBA – AstraZeneca’s promotional regulatory affairs review ...
Following the FDA’s September announcement of a crackdown on direct-to-consumer drug marketing practices and the subsequent flurry of untitled and warning letters criticizing dozens of Big Pharma ads, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback